REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

February 20, 2027

Study Completion Date

May 12, 2027

Conditions
Venous Thromboembolism (VTE)
Interventions
DRUG

REGN7508

Administered per the protocol

DRUG

Apixaban

Administered per the protocol

DRUG

Enoxaparin

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Trial Locations (7)

21215

RECRUITING

Sinai Hospital of Baltimore, Inc., Baltimore

33321

RECRUITING

Phoenix Clinical Research, Tamarac

34232

RECRUITING

Gulfcoast Research Institute, Sarasota

77401

RECRUITING

HD Research - First Surgical Hospital, Bellaire

78229

RECRUITING

Flourish Research - San Antonio (Formerly Clinical Trials of Texas), San Antonio

80113

RECRUITING

Denver Metro Orthopedics, P.C. Englewood Location, Englewood

92504

RECRUITING

CARI Clinical Trials, Riverside

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY